Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. We are working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential.
Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a deeply experienced management team with some 200 years of drug development experience. We are backed by $32.5 million in funding from high-quality investors and have a rich portfolio of compounds.
Our approach is to conduct small, efficient studies that are data rich to establish proof of concept and determine optimal dosing before moving into phase II studies, four of which are planned for 2008.
Click here to print this page